Edward Hæggström
CEO, Nanoform
Edward worked with Jouko Yliruusi, a professor in pharmaceutical technology, at the University of Helsinki to develop a novel particle engineering technology, which led to the founding of Nanoform. The Controlled Expansion of Supercritical Solutions technology can create nanoformulations with higher drug loading, improved bioavailability, and better release profiles. Edward has previously held the role of visiting professor of physics at Harvard Medical School, visiting scholar (assistant professor) of physics at Stanford University and project leader at the CERN.
“In my view, the most important development in drug discovery or development in the last five years has been the advancement of AI. AI has formed an enduring, albeit tangential, theme throughout my academic career, and its evolution over the decades has been remarkable. However, with current computing power, I think the latest developments in AI will have a particularly significant impact.
“Personalized medicine and gene therapy are also major areas of development, but AI's potential to revolutionize drug formulation is especially exciting. AI could transform how we understand and manipulate the size effect to achieve physiological outcomes. Although we're not quite there yet, I believe AI can deliver on this promise.”
